

Children's Mercy Kansas City

SHARE @ Children's Mercy

Research Days

GME Research Days 2023

May 9th, 11:30 AM - 1:30 PM

Inpatient Insulin Management for Severe Hypertriglyceridemia in Pediatrics

Erica Wee

Ryan McDonough

Children's Mercy Hospital

Matthew M. Feldt

Children's Mercy Hospital

Let us know how access to this publication benefits you

Follow this and additional works at: <https://scholarlyexchange.childrensmercy.org/researchdays>



Part of the [Endocrinology, Diabetes, and Metabolism Commons](#), and the [Pediatrics Commons](#)

Wee, Erica; McDonough, Ryan; and Feldt, Matthew M., "Inpatient Insulin Management for Severe Hypertriglyceridemia in Pediatrics" (2023). *Research Days*. 9.

https://scholarlyexchange.childrensmercy.org/researchdays/GME_Research_Days_2023/ResearchDay2/9

This Abstract is brought to you for free and open access by the Conferences and Events at SHARE @ Children's Mercy. It has been accepted for inclusion in Research Days by an authorized administrator of SHARE @ Children's Mercy. For more information, please contact hlsteel@cmh.edu.

Inpatient Insulin Management for Severe Hypertriglyceridemia in Pediatrics

Erica Wee, M.D., Ryan McDonough, D.O., Matthew Feldt, D.O.

Division of Endocrinology and Diabetes, Children's Mercy Kansas City; Kansas City, MO

Introduction

- Severe hypertriglyceridemia (SHTG) is defined as triglyceride (TG) \geq 1000 mg/dL.
- SHTG increases the risk of developing acute pancreatitis.
- Insulin activates lipoprotein lipase which accelerates chylomicron degradation leading to a rapid decrease in TG levels.
- There is a paucity of pediatric standard of care for insulin use to treat SHTG.
- Objective:** To develop a protocol to standardize SHTG management using insulin infusion and decrease the duration of SHTG resolution while preventing hypoglycemia.

Methods

- Endocrinology, Evidence-Based Practice, Hospital Medicine, Critical Care, Gastroenterology, Pharmacy, and Nursing met to develop the protocol.
- Pediatric and adult literature were reviewed, and the protocol (Figure 1) was based on consensus as evidence was limited.
- Retrospective chart review of patients with SHTG during the protocol implementation and from the year prior, for comparison, were reviewed. This study was determined exempt by our institution's IRB.

Results

- The protocol was used in 3 patients and compared to 4 patients the year prior to protocol implementation. Characteristics in Table 1.

Figure 1

Aims:

- Decrease TG level with the use of insulin.
- Dextrose infusion in parallel to prevent hypoglycemia and/or maintain euglycemia.



Initial management:

- Check BMP, TG, lipase and CBC
- Begin insulin drip and IVF
 - Insulin at 0.1 unit/kg/hr
 - D10NS with 20 mEq/L of potassium acetate and 20 mEq/L of potassium phosphate at 1.5x maintenance
- NPO
- Pain control as needed
- Consider Endocrine and/or GI consult



Further management:

- Monitor POC BG
 - Check 15 minutes after insulin start and after any insulin rate change
 - Hourly, once stable
- Check BMP and TG every 6 hours
- Clinical assessment for fluid overload
- Insulin drip
 - Increase rate in increments of 0.05 unit/kg/hr about q6h as tolerated
- If chloride $>$ 115 mmol/L, IVF switch to D10 1/2 NS with 20 mEq/L of potassium acetate and 20 mEq/L of potassium phosphate

Criteria to discontinue insulin drip and IVF

- TG $<$ 500 mg/dL
- For TG 500-1000 mg/dL- discuss with Endocrine
- Start clear liquid diet and advanced to low fat diet as tolerated
 - If tolerating oral intake, then discontinue IVF

Criteria for discharge

- TG $<$ 1000 mg/dL
 - Tolerating oral intake
- *Once oral intake resumed, rebound TG up to 1000 mg/dL is expected

Table 1

Table 1. Patient Characteristics	With protocol	Without protocol
Number of patients with SHTG	3	4
<u>Etiology of SHTG</u>		
Known T1D in DKA	0	1
New T1D in DKA	0	1
Known T2D	0	1
New T2D	1	1
PEG- asparaginase	1	0
Unknown (lost to follow-up)	1	0
<u>Triglyceride (mg/dL)</u>		
Prior to insulin	1001-1168	1194-7357
At time of insulin discontinuation	257-396	415-864
<u>Insulin</u>		
Rate (unit/kg/hour)	0.1-0.25	0.1-0.4
Duration (hours)	13-245	9-222
Presence of hypoglycemia	None	Multiple

Discussion

- Patient with protocol use:** None had DKA. The maximum rate of insulin was 0.25 unit/kg/hr and was achieved for the PEG-asparaginase patient who was on 20% dextrose given the presence of central line.
- Patient without protocol use:** The 2 Type 1 diabetes (T1D) also presented in DKA, where insulin infusion was continued after DKA resolution due to persistent SHTG. It is worthwhile noting that the new diagnosis of diabetes had a shorter resolution of SHTG between 9-38 hours compared to the known diabetes.

Conclusion

- A protocol to standardize the management of SHTG using insulin infusion was developed.
- Despite no difference in IV insulin infusion duration, patients with SHTG where the protocol was used did not have hypoglycemia.
- The protocol has been used on a limited number of patients since implementation to be able to evaluate its effectiveness.

Acknowledgments

- Department of Evidence-Based Practice of Children's Mercy Kansas City: Kathleen Berg, MD, Jackie Bartlett, PhD, RN, Andrea Melanson, OTD, OTR/L.
- Other Departments: Lynn Fullenkamp, MD (Hospital Medicine), Nadia Ibrahim, MD (Gastroenterology), Asdis Wagner, DO (Critical Care), Lisa Enlow, PharmD, Deanna Porter, MSN, RN

Contact information: ewee@cmh.edu